Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Transcode Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 18 | 11 | −7 |
| Shares | 345.2K | 262.2K | −83.0K (−24.0%) |
| Value | $222.5K | $88.6K | −$133.9K (−60.2%) |
New holders (2)
Institutions that held Transcode Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| One68 Global Capital, LLC | 30,120 | $10.2K | 0.01% |
| Warberg Asset Management LLC | 20,000 | $6.77K | 0.00% |
Sold out (9)
Institutions that held Transcode Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Cahill Wealth Management, LLC | 47,060 | $22.9K |
| HRT Financial LP | 25,995 | $17.0K |
| Susquehanna International Group, LLP | 20,854 | $14.0K |
| Virtu Financial LLC | 16,361 | $11.0K |
| Renaissance Technologies LLC | 13,500 | $9.00K |
| Millennium Management LLC | 12,880 | $9.00K |
| Triumph Capital Management | 10,000 | $6.73K |
| Morgan Stanley | 1,165 | $784 |
| UBS Group AG | 1,159 | $777 |